Question · Q1 2024
Inquired about the long-term runway for AviClear's international expansion, the company's R&D innovation strategy, and requested more detail on the impact of GLP-1 drugs on the body contouring business.
Answer
The executive described a long runway for international expansion, with a gradual, multi-year rollout across different markets and territories. R&D efforts are focused on expanding the clinical applications of AviClear for new indications. Regarding GLP-1s, they acknowledged a near-term negative impact on the body contouring business but anticipate a future rebound as patients seek treatment for residual fat and skin laxity after weight loss.